/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. Research To Practice | Oncology Videos
  2. Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 3 with Dr Sara M Tolaney
Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 3 with Dr Sara M Tolaney

Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 3 with Dr Sara M Tolaney

Research To Practice | Oncology Videos · Oct 9, 2026

ADCs like sacituzumab govitecan and Dato-DXD are redefining metastatic TNBC care, guided by biomarker status, sequencing, and toxicity.

Cross-Resistance Limits Clinical Benefit When Sequencing Back-to-Back Topo-1 Payload ADCs

Sequencing one Topo-1 payload ADC directly after another yields diminished patient benefit, even when alternating surface targets like TROP-2 and HER2. Dr. Tolaney notes that while some patients still respond, resistance appears predominantly driven by the chemotherapy payload rather than target mutations.

Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 3 with Dr Sara M Tolaney thumbnail

Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 3 with Dr Sara M Tolaney

Research To Practice | Oncology Videos·a month ago

Sacituzumab Kills Target-Negative Cells by Extracellular Payload Release Before Internalization

Classic ADCs depend on cellular internalization and subsequent membrane permeability to exert bystander cell killing. Sacituzumab govitecan operates differently by releasing its SN-38 payload directly into the extracellular tumor microenvironment prior to entering cancer cells, effectively targeting heterogenous tumors lacking uniform expression.

Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 3 with Dr Sara M Tolaney thumbnail

Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 3 with Dr Sara M Tolaney

Research To Practice | Oncology Videos·a month ago

Built-In Trial Crossover Masks Overall Survival Benefits in ADC Trials

ASCENT-03 did not demonstrate early overall survival separation because 80% of control patients crossed over to sacituzumab upon disease progression. In contrast, Tropion Breast-02 prohibited structured crossover, allowing datopotamab deruxtecan to demonstrate statistically significant improvements across both progression-free and overall survival endpoints.

Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 3 with Dr Sara M Tolaney thumbnail

Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 3 with Dr Sara M Tolaney

Research To Practice | Oncology Videos·a month ago

Distinct Adverse Effects Rather Than Efficacy Dictate First-Line TROP-2 ADC Selection

Sacituzumab govitecan and datopotamab deruxtecan display nearly identical progression-free survival hazard ratios against chemotherapy in PD-L1-negative mTNBC. Clinicians should differentiate based on specific toxicity profiles, weighing datopotamab's mucositis and mandated ocular examinations against sacituzumab's higher frequencies of severe neutropenia and diarrhea.

Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 3 with Dr Sara M Tolaney thumbnail

Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 3 with Dr Sara M Tolaney

Research To Practice | Oncology Videos·a month ago

Network Meta-Analysis Reverses Preferred ADC Sequencing Between Hormone-Positive and Triple-Negative Tumors

Sequencing recommendations for HER2-low metastatic breast cancer diverge according to hormone receptor status. Data indicates that patients with hormone receptor-positive disease benefit most from receiving T-DXD prior to a TROP-2 ADC, whereas patients with triple-negative tumors achieve superior outcomes by starting with a TROP-2 ADC before T-DXD.

Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 3 with Dr Sara M Tolaney thumbnail

Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 3 with Dr Sara M Tolaney

Research To Practice | Oncology Videos·a month ago

Bedtime Low-Dose Olanzapine Salvages Refractory Nausea Caused by Trastuzumab Deruxtecan

Around 5% to 10% of patients receiving trastuzumab deruxtecan continue to suffer from significant emesis despite triple- or quadruple-drug antiemetic regimens. In these refractory cases, adding 2.5 milligrams of olanzapine at bedtime effectively controls acute gastrointestinal distress and helps patients avoid dose modifications.

Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 3 with Dr Sara M Tolaney thumbnail

Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 3 with Dr Sara M Tolaney

Research To Practice | Oncology Videos·a month ago